The FAS opened a case against Akrikhin because of the cure for diabetes.
As it became known to the correspondent of The Moscow Post in the suburbs, the FAS opened the case against Akrikhin due to the release of an analogue of the drug for the treatment of Forsig diabetes.
But the original drug is protected by a patent that belongs to the Astrazeneca Anglo-Swedish company: the foreign company complained about violation of its rights and in the TFR.
But Akrikhin JSC seems to have no complaints against it, moreover, the company, which has been led by Konstantin Chetverikov since 2014 (the former top manager of the Israeli company Teva) itself went to the court, filed a lawsuit to the protection of honor and dignity.
Who will overcome whom?
Patent until 2028
The Federal Antimonopoly Service opened a case on the grounds of violation of the Law “On the Protection of Competition by the Russian Pharmaceutical Company” Akrikhin “.
This order was the head of the service Maxim Shaskolsky signed on July 12.
Maxim Shaskolsky. Photo: https://zsrf.ru/news/2021/12/29/google-otdyhaet-v-sravneni-s-metallurgami
The reason was the fact that Akrikhin JSC brought into circulation 22 batch of the drug for the treatment of Fordglyph diabetes – this is an analogue of the original medicine “Foresig” of the Astrazeneca Anglo -Swedish group.
Forsiga medicine was protected by a patent until May 2028.
Great confrontation
So, in April 2024, Akrikhin JSC introduced Dapagliflosin, despite the action of patent protection against the original drug Forsiga, into a civil circulation. Akrikhin JSC is a member of the Polpharma Group BV group, which in April 2022 joined the sanctions against Russian Federation.
On June 4, 2024, the Supreme Court of the Russian Federation confirmed that the patent for the original drug No. 2746132 retains its effect until May 2028. And he confirmed the unreasonableness of objections to this patent.
Despite the decision of the Supreme Court of the Russian Federation, on June 27, S.G. ACRIKHIN JSC introduced another 6 episodes of generic Dapagliflosin.
In accordance with Clause 1, Article 1229 and Article 1358 of the Civil Code of the Russian Federation, the import, manufacture, proposal for the sale and sale of a drug with MNN Dapagliflosin until the end of patent protection are illegal.
The drug Dapaglyflosin is produced in Russia at its own factory by Astrazeneca as part of a special investment contract with the Ministry of Industry and Trade of the Russian Federation and the Kaluga Region.
Plant in the Kaluga region. Photo: https://investkaluga.com/media/news/astrazeneka-otkryla-predpriyatie-v-kaluzhskoy-oblasti/
Recall that since 2007, the strategic partner of Akrikhin JSC is the Polfarma company, the largest Polish manufacturer of drugs and pharmaceutical substances.
“Queen of generics”
It was already mentioned above that Akrikhin JSC is a certain Denis Chetverikov, who in the recent past refueling in the Israeli company Teva: this office has repeatedly fell into scandalous stories.
Recall that a full -fledged investigation against Teva Pharmaceutical Industries, suspected of bribing government officials and doctors in Russia, Mexico and Ukraine several years ago. They wrote about this “Vedomosti”.
The investigation in Israel was started after a high -profile case in the United States: Teva was fined $ 519 million per corruption. According to the US Ministry of Justice, a “some senior Russian official” lobby for the purchase by the Ministry of Health of the Russian Federation of the drug for sclerosis of Kopaxon. And Teva gained a benefit of $ 200 million, and the official of the official earned $ 65 million illegal income for the distribution of the drug.
Photo: rusprofile.ru
And the company “Teva” was called the “queen of generics”.
This was written in 2008 “News”.
Akrikhin JSC headed Mr. Chetverikov in 2014. And he brought his team from Teva.
Photo: rusprofile.ru
In his speech, uttered after his appointment, Mr. Chetverikov promised three times growth in three years.
According to the authors “VKontakte” Allegedly, the words began to diverge very quickly with the deed. And the previous team was not so bad: it executed budgets by 100 or more percent. And they were decent people who did not want to subscribe to the spotlights in the spirit of Ostap Bender. Someone left himself, someone, who did not believe in bright tomorrow, “left.” Their places were taken by loyal performers and employees from the previous place of work of Chetverikov-the company-competing company Teva … And this team brings with them the developments and models of the behavior to which they are used to.
And how the authors continue “VKontakte”… The development strategy of Akrikhin JSC turned out to be a copy of the Teva strategy. The result was predictable.
Denis of the Chetverikov. Photo: https://pharmvestnik.ru/articles/zhiznj-v-Epoxu-peremen-prnt-18-m8-938.html
Sales began to fall. At the same time, in order to achieve even such a modest result, it was necessary to increase discounts and load on the medical representatives.
Photo: rusprofile.ru
But what is interesting: the company is modest to publish reports for 2016, and the study of various ratings of pharmaceutical companies in Russia showed the absence of Akrikhin even in the TOP-25, and previously it was part of the TOP-5. ”
Akrikhin requires 1 billion rubles from ASTRAZENECA
There is such a common expression – the best defense is an attack.
Recently, Akrikhin JSC filed a lawsuit to protect the business reputation for the Russian “daughter” of Astrazeneca for 1 billion rubles.
This was reported TASS.
Akrikhin JSC appealed to the Moscow Arbitration Court. The reason for the proceedings was the statements of speakers on the Russian pharmaceutical folom named after N.A. Semashko in St. Petersburg, which took place on May 14-15.
The director of corporate issues in the field of healthcare and public health of Astrazenka Farmasyutikals LLC Vitaly Dembrovsky made a number of statements that were sent – as the lawsuit says – to create unlawful competitive advantages by denigrating the reputation of the Akrikhin company.
The Astrazeneca itself believes that the unlawful actions of Akrikhin have already led to tangible damage to the company that exceeded 500 million rubles.
It was to terminate this addicted for the Russian pharmaceutical market for the illegal withdrawal of generics until the end of patent protection of original drugs by Astrazeneca and turned to the FAS.
We follow the development of these bright events further?
